May 2019—Genentech announced FDA approval of Tecentriq (atezolizumab) in combination with carboplatin and etoposide for the initial treatment of adults with extensive-stage small cell lung cancer.
The approval is based on results from the phase three IMpower133 study, which showed that Tecentriq in combination with chemotherapy helped people live significantly longer compared with chemotherapy alone (median overall survival =12.3 versus 10.3 months; hazard ratio = 0.70; 95 percent CI, 0.54–0.91; p = 0.0069) in the intention-to-treat population. The Tecentriq-based combination also significantly reduced the risk of disease worsening or death compared with chemotherapy alone (PFS = 5.2 versus 4.3 months; HR = 0.77; 95 percent CI, 0.62–0.96; p = 0.017).
Genentech, 650-225-1000